RxDoctor Payments Data

Rachel Harvey, APRN

Family · Warner Robins, GANPI 1912373846

Payments from drug & device makers

$2,564in general payments, 2019–2025

Across 175 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$514
  • Lilly USA, LLC$330
  • Boehringer Ingelheim$329
  • Pfizer$211
  • Bayer$168
  • Biohaven Pharmaceuticals, Inc.$143
  • plus $869 from 20 others

What the payments were for

  • Food & beverage$2,50298%
  • Education$622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,564 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$78,949
Medicare patients
223
Services billed
892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$6,942
Olanzapine142$3,094
Sertraline Hcl225$2,330
Buspirone Hcl117$1,634
Trazodone Hcl95$1,590
Quetiapine Fumarate58$1,045
Donepezil Hcl70$840
Escitalopram Oxalate52$680
Duloxetine Hcl34$674
Aripiprazole13$538
Albuterol Sulfate HfaAlbuterol Sulfate17$516
Risperidone30$471
Mirtazapine20$457
Bupropion XlBupropion Hcl23$417
Metoprolol Succinate26$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$6,94212 claims
Lilly USA, LLCOlanzapine$330$3,094142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →